Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology

In oncology, biomarker research aimed to provide insights on cancer biology via positron emission tomography (PET) and single photon emission tomography (SPECT) imaging has seen an incredible growth in the past two decades. Despite the increased number of publications on PET/SPECT radiopharmaceuticals, the field lacked standardization of in vitro and in vivo parameters necessary for the characterization of any radiotracer. Through the efforts of the World Molecular Imaging Society Education Committee, this white paper lays down validation studies that are essential to chemically and biologically characterize new radiopharmaceuticals derived from small molecules, peptides or proteins. Finally, a brief overview of the steps toward translation is also presented. Herein, we discuss the following: Chemistry and radiochemistry metrics to establish the identity of the imaging agent. In vitro and in vivo studies to examine the radiotracer's mechanism of action, which includes target specificity, pharmacokinetics and in vivo metabolism.

Automated summary

This article discusses the validation studies essential for characterizing new radiopharmaceuticals derived from small molecules, peptides or proteins, including the chemistry and radiochemistry metrics to establish the identity of the imaging agent, as well as in vitro and in vivo studies to examine the radiotracer's mechanism of action.